A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia

Hisashi Ishida,Yuta Kawahara,Daisuke Tomizawa,Yasuhiro Okamoto,Asahito Hama,Yuko Cho,Katsuyoshi Koh,Yuhki Koga,Nao Yoshida,Maho Sato,Kiminori Terui,Naoyuki Miyagawa,Akihiro Watanabe,Junko Takita,Ryoji Kobayashi,Masaki Yamamoto…

DOI: https://doi.org/10.1186/s13045-024-01548-3

IF: 28.5

2024-04-30

Journal of Hematology & Oncology

Abstract:Although killer Ig-like receptor ligands (KIR-L) mismatch has been associated with alloreactive natural killer cell activity and potent graft-versus-leukemia (GVL) effect among adults with acute myeloid leukemia (AML), its role among children with AML receiving cord blood transplantation (CBT) has not been determined. We conducted a retrospective study using a nationwide registry of the Japanese Society for Transplantation and Cellular Therapy. Patients who were diagnosed with de novo non-M3 AML and who underwent their first CBT in remission between 2000 and 2021 at under 16 years old were included. A total of 299 patients were included; 238 patients were in the KIR-L match group, and 61 patients were in the KIR-L mismatch group. The cumulative incidence rates of neutrophil recovery, platelet engraftment, and acute/chronic graft-versus-host disease did not differ significantly between the groups. The 5-year event-free survival (EFS) rate was 69.8% in the KIR-L match group and 74.0% in the KIR-L mismatch group ( p = 0.490). Stratification by CD34 + cell dose into four groups revealed a significant correlation between CD34 + cell dose and EFS in the KIR-L mismatch group ( p = 0.006) but not in the KIR-L match group ( p = 0.325). According to our multivariate analysis, KIR-L mismatch with a high CD34 + cell dose (≥ median dose) was identified as an independent favorable prognostic factor for EFS (hazard ratio = 0.19, p = 0.029) and for the cumulative incidence of relapse (hazard ratio = 0.09, p = 0.021). Our results suggested that higher CD34 + cell doses are crucial for achieving a potent GVL effect in the context of KIR-L-mismatched CBT.

oncology,hematology

What problem does this paper attempt to address?

This paper attempts to explore the relationship between killer - cell immunoglobulin - like receptor ligand (KIR - L) mismatch and clinical outcomes in children with acute myeloid leukemia (AML) undergoing umbilical cord blood transplantation (CBT). Specifically, by retrospectively analyzing data registered nationwide in Japan, the researchers evaluated the impact of KIR - L mismatch on patient survival rate, recurrence rate, and graft - versus - host disease (GVHD), and paid special attention to the influence of CD34+ cell dose on these outcomes.

### Main questions
1. **Relationship between KIR - L mismatch and clinical outcomes**: The study aims to determine whether KIR - L mismatch will affect the survival rate, recurrence rate, and incidence of GVHD in children with AML undergoing CBT.
2. **Influence of CD34+ cell dose**: The study further explores the role of CD34+ cell dose in the KIR - L mismatch group, especially whether a high - dose CD34+ cell can improve the prognosis of patients.

### Research methods
- **Data source**: Use the nationwide registration data of the Japanese Society for Transplantation and Cellular Therapy.
- **Research subjects**: Children with AML under 16 years old who received CBT for the first time and were in complete remission between 2000 and 2021.
- **Grouping**: Divided into two groups according to KIR - L matching situation: KIR - L matched group and KIR - L mismatched group.

### Main findings
- **Overall survival rate and recurrence rate**: The 5 - year event - free survival rate (EFS) in the KIR - L matched group and the mismatched group was 69.8% and 74.0% respectively, and the difference was not statistically significant (p = 0.490). There were also no significant differences in the 5 - year cumulative recurrence rate and non - recurrence mortality between the two groups.
- **Influence of CD34+ cell dose**:
- In the KIR - L mismatched group, a higher CD34+ cell dose was significantly associated with better EFS (p = 0.006), while this correlation was not observed in the KIR - L matched group (p = 0.325).
- Multivariate analysis showed that the subgroup with KIR - L mismatch and a higher CD34+ cell dose (≥ median) was an independent favorable prognostic factor, which had a significant impact on EFS (hazard ratio = 0.19, p = 0.029) and cumulative recurrence rate (hazard ratio = 0.09, p = 0.021).

### Conclusion
This study found for the first time that in children with AML with KIR - L mismatch, a higher CD34+ cell dose is not only associated with a lower non - recurrence mortality rate, but also with a lower recurrence rate. This indicates that in the context of KIR - L mismatch, a higher CD34+ cell dose is crucial for achieving an effective graft - versus - leukemia (GVL) effect.